The Jynneos vaccine has received approval in Mexico, aiming to protect the most vulnerable groups against monkeypox.

The Federal Commission for the Protection against Health Risks (Cofepris) has approved the Jynneos vaccine for use in Mexico as a preventive measure against monkeypox. This decision follows an extensive analysis of the vaccine's active compounds and its viability for use in the country by the Committee for New Molecules of Cofepris.

The Jynneos vaccine, developed by pharmaceutical company Bavarian Nordic, will be introduced to Mexico for the first time. A multidisciplinary team from Cofepris conducted a rigorous analysis of the scientific evidence provided by Bavarian Nordic and concluded that the vaccine meets the necessary quality, safety, and effectiveness requirements for marketing in Mexico.

Although the Jynneos vaccine has been certified as a biological product, its use will be restricted to adults at a higher risk of exposure to the virus. The general population, including children and pregnant or breastfeeding women, will not be eligible for this vaccine.

A Boost to Public Health

Smallpox was eradicated in Mexico in the 1980s due to successful vaccination campaigns. However, the cessation of these campaigns led to the emergence of new types of smallpox over time, including monkeypox.

According to infectious disease specialist Alejandro Macías, monkeypox has been one of the most recent cases of type 2 smallpox that has gained traction among the population following the Covid-19 pandemic.

The approval of the Jynneos vaccine, which arrived late to Mexico, will serve as a crucial tool in preventing future outbreaks. The vaccine, previously available only in a few countries like the United States, can now be included in Mexico's vaccination scheme.

Prioritizing Vaccination in Major Cities

Macías suggests that the vaccination should initially be administered in areas with the most population and national and international mobility to eradicate monkeypox transmission. Areas such as Mexico City, Guadalajara, and the metropolitan area of Cancún should have the vaccine available to control, if not eradicate, the disease.

Who Should Get Vaccinated?

• Individuals who have had one or more sexually transmitted infections in the last six months.
• People with HIV.
• Individuals undergoing chemotherapy or radiotherapy treatment.
• Those who have had sexual contact with someone at risk of contracting monkeypox.

Side Effects

• Fatigue
• Headache
• Muscle pain
• Redness, swelling, pain, and itching at the injection site.

Monkeypox Symptoms and Recommendations

Symptoms:

• Rash
• Breakouts on face, hands, and feet
• Fever
• Headaches
• Muscle aches
• Back pain
• Chills
• Exhaustion
• Enlargement of lymph nodes

Recommendations:

• Cover lesions with a wet bandage
• Avoid touching the lesions
• Isolate yourself
• Wear a mask
• Wash your hands frequently
• Consult a doctor to start antiviral treatment
• Avoid sharing personal items
• Cover your nose and mouth when sneezing